-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uproleselan Sodium in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uproleselan Sodium in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Uproleselan Sodium in Refractory Acute Myeloid Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uproleselan Sodium in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uproleselan Sodium in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Uproleselan Sodium in Relapsed Acute Myeloid Leukemia Drug...
-
Product Insights
NewNet Present Value Model: GlycoMimetics Inc’s Uproleselan sodium
Empower your strategies with our Net Present Value Model: GlycoMimetics Inc's Uproleselan sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewSickle Cell Disease With Vaso-Occlusive Crisis – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease With Vaso-Occlusive Crisis – Drugs In Development, 2024 report and make more profitable business decisions. Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration, and infection. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, blood transfusion, and surgery. The Sickle Cell Disease With Vaso-Occlusive Crisis drugs in development market...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis...
-
Product Insights
NewNet Present Value Model: Sangamo Therapeutics Inc’s Isaralgagene Civaparvovec
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...